GH Research (NASDAQ:GHRS) Now Covered by Analysts at Guggenheim

Analysts at Guggenheim started coverage on shares of GH Research (NASDAQ:GHRS) in a research report issued to clients and investors on Thursday,Briefing.com Automated Import reports. The firm set a “buy” rating and a $32.00 price target on the stock. Guggenheim’s price objective suggests a potential upside of 181.94% from the company’s current price.

Several other brokerages have also weighed in on GHRS. Cantor Fitzgerald started coverage on shares of GH Research in a research report on Thursday, February 13th. They issued an “overweight” rating and a $14.00 price objective on the stock. Royal Bank of Canada started coverage on shares of GH Research in a research report on Friday, March 7th. They issued an “outperform” rating and a $31.00 price objective on the stock. Canaccord Genuity Group dropped their price objective on shares of GH Research from $31.00 to $28.00 and set a “buy” rating on the stock in a research report on Monday, November 18th. HC Wainwright reissued a “buy” rating and issued a $40.00 price objective on shares of GH Research in a research report on Monday, January 27th. Finally, Stifel Nicolaus increased their price objective on shares of GH Research from $18.00 to $32.00 and gave the company a “buy” rating in a research report on Thursday, February 27th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $30.86.

GH Research Trading Up 4.9 %

NASDAQ GHRS opened at $11.35 on Thursday. The firm’s fifty day moving average price is $11.03 and its two-hundred day moving average price is $9.18. GH Research has a 1 year low of $6.00 and a 1 year high of $20.50. The firm has a market capitalization of $590.52 million, a P/E ratio of -14.37 and a beta of 0.94.

GH Research (NASDAQ:GHRS) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.06. On average, research analysts anticipate that GH Research will post -0.8 EPS for the current fiscal year.

Hedge Funds Weigh In On GH Research

Several institutional investors and hedge funds have recently modified their holdings of GHRS. BNP Paribas Financial Markets acquired a new stake in GH Research during the fourth quarter worth about $44,000. Two Sigma Investments LP acquired a new stake in GH Research during the fourth quarter worth about $117,000. Millennium Management LLC acquired a new stake in GH Research during the fourth quarter worth about $145,000. AdvisorShares Investments LLC grew its stake in GH Research by 15.4% during the fourth quarter. AdvisorShares Investments LLC now owns 36,011 shares of the company’s stock worth $252,000 after buying an additional 4,806 shares in the last quarter. Finally, Northern Trust Corp boosted its stake in shares of GH Research by 26.8% in the 4th quarter. Northern Trust Corp now owns 40,834 shares of the company’s stock valued at $286,000 after purchasing an additional 8,641 shares in the last quarter. 56.90% of the stock is currently owned by institutional investors and hedge funds.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).